XOLAIR sol inj 150 mg/1ml (n ser pré) 1 ml
7680680300053
CH-68030
R03DX05
03.04.5.
Reimbursement limitations:
XOLAIR.01
Asthme allergique sévère résistant à d'autres thérapies. Prescription par un spécialiste (pneumologue, allergologue). La prescription …
1 / 3
google
Details
- Product number
- 6803002
- CPT
- -
- Packaging group
- 1
- Unit
- Fertigspritze(n)
- Composition
- omalizumabum 150.00 mg, arginini hydrochloridum, histidini hydrochloridum monohydricum, histidinum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1.00 ml.
Articles (1)
Xolair 150 mg/1.0 ml, Injektionslösung in einer Fertigspritze
Injektionslösung
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
150.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 417.05
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/12/2024
Authorization holder
Novartis Pharma Schweiz AG
6343 Risch
Authorization information
- Swissmedic authorization number
- 68030
- Drug name
- Xolair, Injektionslösung in einer Fertigspritze
- Galenic form
- INLFS
- ATC Code
- R03DX05
- Authorization status
- Z
- Dispensation category
- B
- First authorization
- 08/04/2021
- Authorization expiration date
- 07/04/2026
- IT number
- 03.04.5.
- Domain
- Human medicine
Packaging details
- Description (FR)
- XOLAIR sol inj 150 mg/1ml (n ser pré) 1 ml
- Description (DE)
- XOLAIR Inj Lös 150 mg/1ml (n Fertspr) 1 ml
- Market launch
- 08/04/2021
- Narcotic (BTM)
- No